About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 71295 record(s)
Req # A-2024-000097
Pfizer was to submit a data/report package to Health Canada by December 1, 2023 with respect to SV40 Deoxyribonucleic acid (DNA) contamination in their covid vaccines. Pfizer described what they would provide to Health Canada as follows: "…Organization: Health Canada
August 2024
Req # A-2024-000120
March 2023 notification from Health Canada to Indiva of its determination that the Indiva Wild Cherry Tetrahydrocannabinol (THC) Lozenges and Life Lemon THC Lozenges in their 100 mg, 250 mg and 500 mg THC per package formats have been improperly…Organization: Health Canada
August 2024
Req # A-2024-000122
The name of the company (sponsor) who submitted the Second Semaglutide Abbreviated New Drug Submission (ANDS); and the year and month in which the Second Semaglutide ANDS was accepted for review. Per Health Canada’s Notice: Expansion of the Generic…Organization: Health Canada
August 2024
Req # A-2024-000123
In respect of the second, newest Abbreviated New Drug Submission (ANDS) for semaglutide (the Second Semaglutide ANDS), please provide a copy of the most recent Certified Product Information Document (CPID) submitted by the sponsor.Organization: Health Canada
August 2024
Req # A-2024-000125
In respect of the second, newest Abbreviated New Drug Submission (ANDS) for semaglutide (the Second Semaglutide ANDS), please provide a copy of any Screening Acceptance Letter sent by Health Canada to the sponsor of the Second Semaglutide ANDS.Organization: Health Canada
August 2024
Req # A-2024-000140
Records detailing the number of full-Time “exempt staff”, their titles & related costs. Break down annually by fiscal year from 2014-2024.Organization: Health Canada
August 2024
Req # A-2024-000149
All records and documentation for health product recall number RA-72773. Records confirming the basis for the Recall, as well as any representations or communications. Date range January 1, 2015 to April 17, 2020.Organization: Health Canada
August 2024
Req # A-2024-000157
For each communication number referenced below, provide all material associated with the meetings or activities listed in the Registry of Lobbyists for Pfizer: 15283-470669, 15283-491740, 15283-495755, 15283-495757, 15283-498868, 15283-498870, 15283…Organization: Health Canada
August 2024
Req # A-2024-000215
Documents referred to in Health Canada’s External Fee Charging Guidelines Document (available here: https://publications.gc.ca/collections/collection_2007/hcsc/H21-293-5-2007E.pdf).Organization: Health Canada
August 2024
Req # A-2024-000220
Notice(s) of Violation issued to individual(s) or organization(s) under the Cannabis Act or its Regulations, as referenced on the following webpage: Administrative monetary penalties under the Cannabis Act - Canada.ca.Organization: Health Canada
August 2024